Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q8WVQ1: Variant p.Arg300His

Soluble calcium-activated nucleotidase 1
Gene: CANT1
Feedback?
Variant information Variant position: help 300 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Histidine (H) at position 300 (R300H, p.Arg300His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In DBQD1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 300 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 401 The length of the canonical sequence.
Location on the sequence: help YLIHESACWSDTLQRWFFLP R RASQERYSEKDDERKGANLL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         YLIHESACWSDTLQRWFFLPRRASQERYSEKDDERKGANLL

Mouse                         YLIHESACWSDTLQRWFFLPRRASHERYSEKDDERKGSNLL

Rat                           YLIHESACWSDTLQRWFFLPRRASHERYSEREDERKGSNLL

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 401 Soluble calcium-activated nucleotidase 1
Topological domain 63 – 401 Lumenal
Binding site 284 – 284
Alternative sequence 246 – 401 Missing. In isoform 2.
Mutagenesis 287 – 287 C -> S. Reduces GDPase and ADPase activities 1.3-fold.
Mutagenesis 301 – 301 R -> A. Reduces activity by 99%.
Mutagenesis 308 – 308 S -> C. Reduces GDPase activity 1.3-fold and ADPase activity 2-fold. Severe loss of dimer formation; when associated with S-287.
Mutagenesis 317 – 317 A -> C. Reduces GDPase activity 1.7-fold and ADPase activity 1.5-fold. Severe loss of dimer formation; when associated with S-287.
Beta strand 300 – 305



Literature citations
Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis.
Nizon M.; Huber C.; De Leonardis F.; Merrina R.; Forlino A.; Fradin M.; Tuysuz B.; Abu-Libdeh B.Y.; Alanay Y.; Albrecht B.; Al-Gazali L.; Basaran S.Y.; Clayton-Smith J.; Desir J.; Gill H.; Greally M.T.; Koparir E.; van Maarle M.C.; Mackay S.; Mortier G.; Morton J.; Sillence D.; Vilain C.; Young I.; Zerres K.; Le Merrer M.; Munnich A.; Le Goff C.; Rossi A.; Cormier-Daire V.;
Hum. Mutat. 33:1261-1266(2012)
Cited for: FUNCTION IN PROTEOGLYCAN SYNTHESIS; VARIANTS DBQD1 HIS-300; ARG-303 AND ASN-374; Identification of CANT1 mutations in Desbuquois dysplasia.
Huber C.; Oules B.; Bertoli M.; Chami M.; Fradin M.; Alanay Y.; Al-Gazali L.I.; Ausems M.G.; Bitoun P.; Cavalcanti D.P.; Krebs A.; Le Merrer M.; Mortier G.; Shafeghati Y.; Superti-Furga A.; Robertson S.P.; Le Goff C.; Muda A.O.; Paterlini-Brechot P.; Munnich A.; Cormier-Daire V.;
Am. J. Hum. Genet. 85:706-710(2009)
Cited for: VARIANTS DBQD1 LEU-299; CYS-300 AND HIS-300;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.